Dear Mr./Ms.,
Sanyou Biopharmaceuticals focuses on providing integrated solution for therapeutic antibody discovery and development, and offers all sorts of services for therapeutic antibody R&D.
In terms of antibody discovery, we developed antibody phage display libraries based on mouse immunization, which combine the advantages of hybridoma and phage display technology. We could screen dozens of high-affinity candidate antibodies in just two months.

1) Affinity: High affinity guaranteed by the affinity maturation in vivo;
2) Efficiency: Save THREE months compared to hybridoma;
3) Yield: DOZENS of high-affinity lead antibody candidates;
4) Clarity: Antibody sequences are clear, no additional sequencing steps required.
Make your ideal mAbs to come true!

1) Gene synthesis costs an additional week;
2) The average yield of one-time production is ~1 mg purified antibody.

E4A is a candidate antibody obtained from the mouse antibody library. In the in vitro phagocytosis assay, E4A effectively blocked the "don't eat me" signal and significantly enhanced the phagocytosis of target cells by macrophages (Fig. 1). In the animal experiment, E4A also effectively inhibited tumor growth in NOD-SCID mice (Fig. 2). Meanwhile, its performance was stronger than that of the control antibody in both in vivo and in vitro efficacy evaluations.

Do you need assistance with antibody discovery?


Sanyou Biopharmaceuticals is a leading international High-tech biotechnology company focused on research, development and providing integrated solutions for innovative antibody drug developments.
Sanyou Bio is committed to building world-leading antibody drug discovery and development platforms of high-quality, high-throughput, integrated R&D and value transformation. Sanyou Bio is dedicated in constructing a business ecosystem for therapeutic, R&D and diagnostic products and services, and collaborating with global biopharmaceutical, diagnostic, R&D companies to open a new era for the diagnosis and treatment of human diseases.
Since the founding in the year of 2015, Sanyou Bio has been growing rapidly. As of May 2021, Sanyou Bio has a professional team of more than 160 employees, of which more than 70% hold a PhD or master degree, and this team is deeply experienced in R&D and industrialization of innovative drugs. Sanyou Bio has established an integrated R&D laboratory of several thousands of square meters with advanced facilities in Caohejing Hi-Tech Park in Shanghai. The laboratory have 10 functional modules and more than 40 core technology platforms, led by a series of super-trillion phage display antibody libraries, and followed by a full range of essential R&D platforms for innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, pharmaceutical properties analysis, cell line construction, and process development. Sanyou Bio continues to provide new technologies, new products, services and solutions of "best quality, fastest speed and lowest cost". Sanyou Bio has established friendly business relationships with more than 100 pharmaceutical companies, drug development organizations and diagnostic product development companies around the world.
"Excellence and innovation, pursuit of dreams, striving and evolving, for the benefit of patients", holding these principles and beliefs, Sanyou Bio looks forward to working with our customers and partners to build a long-term synergistic growth ecosystem and a healthy society.

You're welcome to send an email and tell us what's your need, and we will get back to you ASAP.


Customer Specialist
Sanyou Biopharmaceuticals Co., Ltd.
Address: Building 6, No.188 Xinjunhuan Road,
Minhang District, Shanghai, China 201114
Tel: +86-21-3368 1627